|
Tumor Cell Invasion
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
The purpose of this study was to evaluate whether ClC-3 influences the migration and invasion of cervical squamous cell carcinoma cells and its possible mechanisms.
|
30905432 |
2019 |
|
Tumor Cell Invasion
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
Mechanistic studies suggested that canonical TGF-β/Smad signaling pathway is involved in CLC-3-induced gastric cancer cells proliferation, migration and invasion.
|
29795988 |
2018 |
|
Tumor Cell Invasion
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
Furthermore, higher expression of CLC-3 was correlated with deeper tumor invasion (P = 0.006) and increased lymph node metastasis (P = 0.016), and knockdown of CLC-3 inhibited cell proliferation and migration in vitro.
|
30217218 |
2018 |
|
Tumor Cell Invasion
|
0.060 |
AlteredExpression
|
phenotype |
BEFREE |
Silencing endogenous CLC-3 with ShCLC-3 adenovirus significantly decreases volume-regulated chloride currents, inhibits the nuclear translocation of p65 subunit of Nuclear Factor-κB (NF-κB), decreases transcriptional activity of NF-κB, reduces MMP-3 and MMP-9 expression and decreases glioma cell migration and invasion.
|
28969029 |
2017 |
|
Tumor Cell Invasion
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
An ITALIC! in vitro investigation of the effect of ClC-3 on the migration and invasion of ectopic ESCs from patients with endometriosis.
|
26965430 |
2016 |
|
Malignant neoplasm of breast
|
0.050 |
Biomarker
|
disease |
BEFREE |
To assess the roles of CLCN3 in breast cancer, we next performed three-dimensional (3D) spheroid proliferation analyses using MCF10A-ErbB2 cells treated with MCF10A-neo-derived exosomes or CLCN3 shRNA stably expressing SKBR3 and MDA-MB-453 breast cancer cells.
|
31608175 |
2019 |
|
Malignant neoplasm of breast
|
0.050 |
Biomarker
|
disease |
BEFREE |
Double transgenic MMTV-PyMT/CLCN3 mice with spontaneous mammary cancer and ClC-3 overexpression demonstrated drug resistance to PTX and DOX.
|
30230544 |
2019 |
|
Breast Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
To assess the roles of CLCN3 in breast cancer, we next performed three-dimensional (3D) spheroid proliferation analyses using MCF10A-ErbB2 cells treated with MCF10A-neo-derived exosomes or CLCN3 shRNA stably expressing SKBR3 and MDA-MB-453 breast cancer cells.
|
31608175 |
2019 |
|
Breast Carcinoma
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
ClC-3 was highly expressed in the P-glycoprotein (P-gp)-dependent human lung adenocarcinoma cell line (A549)/paclitaxel (PTX) and the human breast carcinoma cell line (MCF-7)/doxorubicin (DOX) resistant cells.
|
30230544 |
2019 |
|
Malignant neoplasm of breast
|
0.050 |
Biomarker
|
disease |
BEFREE |
The aim of the present study is to explore the molecular mechanisms underlying the antitumor effect of silencing ClC-3 in breast cancer.
|
29963105 |
2018 |
|
Malignant neoplasm of breast
|
0.050 |
Biomarker
|
disease |
BEFREE |
In the present study, we showed the involvement of intracellular organelle ClC-3 Cl<sup>-</sup> /H<sup>+</sup> transporter in HER2 transcription in breast cancer MDA-MB-453 cells.
|
29949674 |
2018 |
|
Malignant neoplasm of breast
|
0.050 |
Biomarker
|
disease |
BEFREE |
Pharmacological modulation of ClC-3 may provide a deep understanding in antiestrogen treatment of breast cancer patients.
|
28419445 |
2018 |
|
Breast Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
The aim of the present study is to explore the molecular mechanisms underlying the antitumor effect of silencing ClC-3 in breast cancer.
|
29963105 |
2018 |
|
Breast Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Pharmacological modulation of ClC-3 may provide a deep understanding in antiestrogen treatment of breast cancer patients.
|
28419445 |
2018 |
|
Breast Carcinoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
In the present study, we showed the involvement of intracellular organelle ClC-3 Cl<sup>-</sup> /H<sup>+</sup> transporter in HER2 transcription in breast cancer MDA-MB-453 cells.
|
29949674 |
2018 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
In this research, we explore the ClC-3 expression in cervical carcinoma and its underlying clinical significance, trying to illuminate ClC-3 probable function in the neoplasm malignant behavior, development and prognosis.
|
30636929 |
2019 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
Chloride channel-3 mediates multidrug resistance of cancer by upregulating P-glycoprotein expression.
|
30230544 |
2019 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
In this research, we explore the ClC-3 expression in cervical carcinoma and its underlying clinical significance, trying to illuminate ClC-3 probable function in the neoplasm malignant behavior, development and prognosis.
|
30636929 |
2019 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
Chloride channel-3 mediates multidrug resistance of cancer by upregulating P-glycoprotein expression.
|
30230544 |
2019 |
|
Malignant Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
High-grade expression of cytoplasmic ClC-3 predicted poor survival in cancer patients.
|
25537517 |
2015 |
|
Primary malignant neoplasm
|
0.040 |
AlteredExpression
|
group |
BEFREE |
High-grade expression of cytoplasmic ClC-3 predicted poor survival in cancer patients.
|
25537517 |
2015 |
|
Malignant Neoplasms
|
0.040 |
Biomarker
|
group |
BEFREE |
ClC-3 may be a new target for cancer therapies.
|
18359479 |
2008 |
|
Primary malignant neoplasm
|
0.040 |
Biomarker
|
group |
BEFREE |
ClC-3 may be a new target for cancer therapies.
|
18359479 |
2008 |
|
Liver carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Moreover, up-regulation of CIC-3 markedly correlated with tumor size and overall prognosis, suggesting that CIC-3 expression could predict both tumor size and overall prognosis in hepatocarcinoma.
|
30678806 |
2019 |
|
Liver carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
In conclusion, we demonstrated that ClC-3 can arrest the cell cycle at the G1 phase to inhibit cell proliferation, suggesting that ClC-3 has the potential to be a novel target for HCC therapy and potentially improve the prognosis of HCC patients.
|
29749557 |
2018 |